Korea Now Reimburses BeOne’s Tevimbra First-Line in Three Cancers, Using PD-L1 Cutoffs to Set the Limits
One reimbursement decision moved a second-line PD-1 into first line across three common cancers, inside biomarker limits.
PD-1
Merck Moved Every Japanese Keytruda Indication to a One-Minute Injection on a Single Lung Cancer Trial
One exposure trial in lung cancer carried every Japanese indication. The contest is now minutes and millilitres.
Replimune Won Accelerated Approval on 91 Evaluable Patients and a 24% Response Rate
CBER took a 24% response in 91 evaluable patients, one day after the same committee voted nine to three against Capricor. Measurement, not size.
The EPO Revoked BMS’s 480mg Opdivo Patent Because the Trial Behind It Dosed by Weight
BMS claimed a 480mg flat dose. The only clinical example in its filed application dosed by weight. The EPO revoked the patent on added matter.
OncoC4 merged with AcroImmune
OncoC4, a biopharmaceutical firm in its final phases of developing advanced cancer therapies, is merging with AcroImmune, a developer of immunotherapies for malignant tumors and inflammatory diseases. The merger produces first- and best-in-class immunotherapies. Drs. Yang Liu and Pan Zheng co-founded OncoC4 and AcroImmune, and they share a common shareholder base. The combined firm was … Read more